Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

Inclusion Criteria:

Any biopsy or cytologically proven resectable or unresectable primary or secondary (metastatic) malignancy in the lung; this is defined as

Tumors whose only remaining residual deposits are confined to the lungs OR
Oligometastatic tumors with > 80% of measurable tumor volume in the target lung In both of the above situations, no clinical evidence of central nervous system (CNS) metastases can exist; oligometastatic disease is difficult to define but would, as a guideline, have only 1-4 loci of disease established in 1-2 organ systems outside the affected lung; exceptions to these guidelines can occur, particularly in cases where sites of metastatic disease are equivocal or so minute that it would not exceed 20% of tumor volume
Unresectable stage IV non-small cell lung cancer (NSCLC)
Unresectable stage IIIB NSCLC
Resectable metastatic sarcoma to lung (thoracoscopically resectable)
Other malignancies that meet the criteria
Eastern Cooperative Oncology Group performance status 0-1
No oxygen needs (oxygen use per standard established criteria for oxygen requirements)
Modified Borg dyspnea scale < 5
Six minute walk >= 50% of the expected distance; this will not be used as exclusion criteria if due to a reason other than respiratory per judgment of physician e.g., pain
Ambulatory and resting oxygen (O2) saturation > 88%

PPO (predicted post operative)* forced expiratory volume in one second (FEV1) >= 50% predicted

PPO values should be calculated for each patient

PPO * diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% predicted

PPO values should be calculated for each patient

PPO * vital capacity >= 50% predicted

PPO values should be calculated for each patient
Granulocytes > 1,500 ul
Platelets >= 100,000 ul
Patients must sign a study-specific consent form prior to registration
Tumor anatomy must allow the isolated lung suffusion in the judgment of the principal investigator (PI)

Exclusion Criteria:

Uncontrolled intercurrent disease
Prior chemotherapy for proven metastatic disease within 4 weeks
Evidence of pulmonary toxicity from previous or ongoing chemotherapy
Creatinine > 1.5 mg/dL
Liver enzymes > 2 times upper normal
Uncontrolled congestive heart failure (in judgment of the PI)
Optional: ejection fraction < 40% for clinical evidence of insufficient cardiac reserve (multi gated acquisition scan [MUGA] or echocardiogram [ECHO] will be done only if indicated in the judgment of the PI)
Myocardial infarction or angina within past 6 months
Contraindications to anticoagulation
Hydration intolerance (e.g., uncontrolled congestive heart failure [CHF])
Human immunodeficiency virus positive (HIV+) on antiretroviral therapy
Pregnant or lactating
Diffuse pulmonary fibrosis involving over 25% of the total lung parenchyma
Previous radiation for thorax
Metastatic sarcoma to lung that is not able to have tumors resected thoracoscopically
Prior lung removal in the affected lung (would have decreased lung volume)